The American Lung Association is increasing efforts to promote biomarker testing for people diagnosed with lung cancer. The organization announced the expansion of its Biomarker Education and Awareness for Testing (BEAT) Lung Cancer initiative, which focuses on improving access to and understanding of biomarker testing, especially in communities that face higher rates of lung cancer.
“Biomarker testing is the key to ensuring that people diagnosed with lung cancer receive the treatment that is most effective for their specific type of cancer,” said Harold Wimmer, President and CEO of the American Lung Association. “Too many people are still going without this critical testing—often due to a lack of awareness, access or insurance coverage. Through the BEAT Lung Cancer campaign, we are working to reach more people with the information, resources and support they need to live longer, more full lives after a lung cancer diagnosis.”
Biomarker testing, sometimes called molecular or genomic testing, examines a tumor’s DNA and protein levels to help identify targeted treatments. This includes measuring levels of proteins like PD-L1, which can indicate whether immunotherapy may be helpful. By understanding what causes tumor growth in each patient, doctors can recommend therapies that may shrink tumors or slow their progression.
However, not all patients are receiving this kind of testing. Research has shown that 23% of patients received chemotherapy and radiation before completing full biomarker testing. This can lead to unnecessary treatments and delays in finding the most effective care options. There are also disparities among different groups: while 26% of eligible white patients received biomarker testing, only 14% of eligible Black patients did.
The expanded BEAT Lung Cancer campaign will work to address barriers such as lack of awareness, limited access, and issues with insurance coverage. More information about the initiative is available at https://www.lung.org/beat-lung-cancer.
